Skip to main content
SpringerLink
Log in

Lisinopril

A Review of its Pharmacology and Clinical Efficacy in the Early Management of Acute Myocardial Infarction

  • Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Synopsis

Following establishment of its efficacy in hypertension and congestive heart failure, the ACE inhibitor lisinopril has now been shown to reduce mortality and cardiovascular morbidity in patients with myocardial infarction when administered as early treatment. The ability of lisinopril to attenuate the detrimental effects of left ventricular remodelling is a key mechanism; however, additional cardioprotective and vasculoprotective actions are postulated to play a role in mediating the early benefit.

The GISSI-3 trial in > 19 000 patients has demonstrated that, when given orally within 24 hours of symptom onset and continued for 6 weeks, lisinopril (with or without nitrates) produces measurable survival benefits within 1 to 2 days of starting treatment. Compared with no lisinopril treatment, reductions of 11% in risk of mortality and 7.7% in a combined end-point (death plus severe left ventricular dysfunction) were evident at 6 weeks. Advantages were apparent in all types of patients. Thus, those at high risk — women, the elderly, patients with diabetes mellitus and those with anterior infarct and/or Killip class >1 — also benefited.

These gains in combined end-point events persisted in the longer term, despite treatment withdrawal after 6 weeks in most patients. At 6 months, the incidence rate for the combined end-point remained lower than with control (a 6.2% reduction).

The GISSI-3 results concur with those from recent large investigations (ISIS-4, CCS-1, SMILE) of other ACE inhibitors as early management in myocardial infarction. However, the results of the CONSENSUS II trial (using intravenous enalaprilat then oral enalapril) were unfavourable in some patients. These findings, together with the development of persistent hypotension and, to a lesser extent, renal dysfunction among patients in the GISSI-3 trial, have prompted considerable debate over optimum treatment strategies.

Present opinion generally holds that therapy with lisinopril or other ACE inhibitors shown to be beneficial may be started within 24 hours in haemodynamically stable patients with no other contraindications; current labelling in the US and other countries reflects this position. There is virtually unanimous agreement that such therapy is indicated in high-risk patients, particularly those with left ventricular dysfunction.

The choice of ACE inhibitor appears less important than the decision to treat; it seems likely that these benefits are a class effect. Lisinopril has a tolerability profile resembling that of other ACE inhibitors, can be given once daily and may be less costly than other members of its class. However, present cost analyses are flawed and this latter point remains to be proven in formal cost-effectiveness analyses.

In conclusion, early treatment with lisinopril (within 24 hours of symptom onset) for 6 weeks improves survival and reduces cardiovascular morbidity in patients with myocardial infarction, and confers ongoing benefit after drug withdrawal. While patients with symptoms of left ventricular dysfunction are prime candidates for treatment, all those who are haemodynamically stable with no other contraindications are also eligible to receive therapy. Lisinopril and other ACE inhibitors shown to be beneficial should therefore be considered an integral part of the early management of myocardial infarction in suitable patients.

Pharmacodynamic Properties

Left ventricular remodelling follows a myocardial infarction and in some patients precedes potentially lethal heart failure. Damage to the cellular and structural components of the heart causes ventricular thinning and expansion of the infarct zone. These events predispose susceptible patients to ventricular enlargement and dysfunction. There is accumulating evidence, although not completely consistent, that the renin-angiotensin-aldosterone system in general and angiotensin II (AII) in particular is a primary modulator of these processes. By inhibiting the actions of AII, ACE inhibitors would be expected to modify such deleterious effects.

As demonstrated by the large GISSI-3 trial, lisinopril attenuates ventricular enlargement when therapy is begun within 24 hours of symptom onset and continued for 6 weeks in patients with myocardial infarction (see also Clinical Efficacy summary). At 6 weeks, left ventricular end-diastolic volume increased by a significantly smaller amount with lisinopril than with no lisinopril (and end-systolic volume tended to show this effect), particularly in the presence of significant left ventricular asynergy. Ejection fraction (EF) did not change significantly; however, the percentage of patients with EF ≤35% (but who did not have clinical signs of congestive heart failure) was lower in lisinopril recipients. According to post-hoc analyses, which require caution in their interpretation, this was also true in high-risk groups (the elderly, those with Killip class >1 and patients with anterior infarcts).

Lisinopril increased peak oxygen consumption during exercise and improved left ventricular diastolic function in other investigations in small numbers of patients with coronary artery disease.

Of interest is the finding that lisinopril reduced the in-hospital incidence of sustained ventricular tachycardia (sVT) and sVT plus ventricular fibrillation in the GISSI-3 trial. A direct electrophysiological action is unlikely. Lisinopril had no effect on potentially arrhythmogenic serum noradrenaline (norepinephrine) levels, although amelioration of sympathetic activity has been demonstrated for other ACE inhibitors.

Other potential cardio- and vasculoprotective effects observed with lisinopril in vitro, in animals, or in humans in some instances, include the following: (i) reductions in left ventricular mass and attenuation of necrotic cell damage; (ii) antioxidant effects; and (iii) increases in bradykinin levels and stimulation of prostacyclin synthesis. Evidence is equivocal for antiplatelet effects or enhancement of fibrinolysis. The possible contribution of these activities to the mechanism of lisinopril in myocardial infarction is undetermined at present.

Pharmacokinetic Properties

Bioavailability of lisinopril is about 20 to 28% in patients with myocardial infarction, similar to that for healthy individuals but greater than the value of 16% recorded for patients with congestive heart failure. Peak serum lisinopril concentrations are reached at about 8 hours after a single 2.5 or 5mg dose in most patients with suspected myocardial infarction. Absorption of lisinopril is not influenced by food. The apparent volume of distribution for lisinopril is 124L and the drug is not bound to plasma proteins.

Lisinopril is not metabolised. Rather, it is excreted unchanged by renal mechanisms which probably include tubular secretion and reabsorption in addition to glomerular filtration. The elimination half-life (t1/2p) of lisinopril is 12.6 hours in healthy volunteers. Most of a dose of lisinopril is eliminated in an early phase, but the drug is still detectable in the later phase, which has a t1/2 of about 30 hours. Steady-state is reached within 2 to 3 days.

Mean renal clearance in patients with myocardial infarction is 3.11 L/h for a 2.5mg dose and 3.76 L/h for a 5mg dose. Clearance of lisinopril in patients with myocardial infarction, as in the elderly and patients with congestive heart failure, is slower than in healthy individuals. Patients with renal impairment require dosage adjustment according to creatinine clearance.

Clinical Efficacy

Lisinopril provides early and prolonged benefits in mortality and cardiovascular morbidity when administered within 24 hours of symptom onset and continued for 6 weeks in patients with acute myocardial infarction. The GISSI-3 trial, conducted in more than 19 000 patients, demonstrated an 11% reduction in risk of all-cause mortality and a 7.7% decrease in combined end-point events (death plus severe left ventricular dysfunction) at 6 weeks, compared with no lisinopril (patients were given thrombolytics, β-blockers and aspirin and were allowed to receive nitrates as standard coronary care).

Most survival gain is accrued within the first few days. Indeed, survival appears to be improved as early as day 1 of lisinopril treatment, as shown by divergent survival curves and reductions in types of cardiac deaths compared with control (no lisinopril). However, no statistics are available for the 1-day data. A sustained, albeit somewhat smaller, benefit in mortality plus cardiovascular morbidity is evident at 6 months despite lisinopril withdrawal after 6 weeks: the incidence of combined end-point events was reduced by 6.2%. The combination of lisinopril plus nitrates produced a significant improvement vs standard care (a 17% mortality risk reduction at 6 weeks and an 8.7% decrease in the combined end-point at 6 months). The lack of demonstrable efficacy with nitrates alone obscures their role in this indication. Lisinopril was associated with improved survival independently of the effects produced by thrombolytics, β-blockers or aspirin.

Patients at the greatest risk also benefit from early treatment with lisinopril. Women, the elderly (>70 years), and patients with Killip class 2 or 3, anterior infarcts or diabetes mellitus experienced reductions in at least 1 measure of outcome at 6 weeks and/or 6 months. Benefit was thus demonstrated in all patient categories, including individuals with Killip class 1 who comprised the majority of patients in GISSI-3.

Tolerability

Lisinopril is associated with an adverse events profile typical of ACE inhibitors. Headache, dizziness, diarrhoea and cough are experienced most frequently. The low incidence of lisinopril withdrawal due to cough in the GISSI-3 trial (0.5%) may relate to the short period of treatment. Older patients with congestive heart failure, but not those with hypertension, have experienced more frequent adverse events than younger patients during lisinopril therapy. General tolerability data for elderly patients with myocardial infarction are not available from GISSI-3.

Persistent hypotension occurs with lisinopril and other ACE inhibitors. This event developed significantly more frequently with lisinopril than with no lisinopril in the pilot study for GISSI-3, and hypotension in general was the main reason for treatment discontinuation in GISSI-3 (9.7% of patients). However, mortality did not increase proportionately in the subgroup of patients who experienced hypotension. Likewise, the risk of renal dysfunction rises in patients receiving lisinopril, especially in high-risk patients, but a proportional rise in mortality was not observed in these patients in GISSI-3. Renal dysfunction developed in 1.8% of all lisinopril recipients in GISSI-3 and caused drug withdrawal in 4.2% of elderly patients.

Other potentially serious adverse events are rare. The incidence of angioedema during lisinopril therapy has ranged from 0.06% to 0.6% in patients with indications other than myocardial infarction, as reported in the literature, but was low (0.01%) in GISSI-3. Anaemia was documented in 0.58% of patients, most with hypertension, in a UK postmarketing study.

Pharmacoeconomic Considerations

Although cost-minimisation studies to date have suggested a possible cost advantage for lisinopril over some other ACE inhibitors, these types of analyses are of limited clinical value unless all outcomes and other costs are equal. Furthermore, acquisition costs vary greatly across markets. The issue of cost effectiveness thus requires evaluation in formal analyses: a cost effectiveness analysis of an ‘all patients’ treatment strategy versus a selective approach is ongoing.

Drug Interactions

Lisinopril does not appear to have an additive adverse hypotensive effect when combined with β-blockers, as shown by GISSI-3. The risk of hyperkalaemia is increased by concomitant potassium-sparing diuretics, and diuretics in general can predispose patients receiving lisinopril to development of renal impairment. Lisinopril can cause lithium toxicity by reducing lithium clearance.

Dosage and Administration

In the early management of acute myocardial infarction, lisinopril may be administered orally within the first 24 hours of symptom onset in haemodynamically stable patients with no other contraindications. Treatment must be conducted under medical supervision in a hospital setting.

The currently recommended dosage of lisinopril is 5mg as a first dose, 5mg 24 hours later, 10mg at 48 hours after the first dose, then 10mg once daily. Duration of treatment is 6 weeks; patients should then be reassessed and treatment continued if warranted by the presence of other conditions (e.g. hypertension, left ventricular dysfunction or congestive heart failure).

Lisinopril dosage should be decreased to 2.5mg in patients with systolic blood pressure (SBP) ≤120mm Hg. If hypotension develops (SBP ≤100mm Hg) the daily maintenance dosage may be 5mg, with a temporary decrease to 2.5mg if required. Persistent hypotension (SBP ≤90mm Hg for ≥1 hour) necessitates lisinopril discontinuation. Lisinopril should be used with caution in patients with, or at risk of, hyperkalaemia or renal impairment. The dosage is reduced in patients with renal dysfunction (creatinine clearance ≤30 ml/min/1.73m2 or serum creat-inine levels ≥2 mg/dl).

Use of ACE inhibitors in the early and late management of myocardial infarction is gaining widespread acceptance as results of large mortality trials are examined and assimilated into treatment protocols. Lisinopril is a non-sulfhydryl ACE inhibitor with established efficacy in congestive heart failure and hypertension. More recently, publication of the GISSI-3 study has centred attention on lisinopril in the early management of acute myocardial infarction. This indication is the sole topic of this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ollivier J-P, Bouchet VA. Prospects for cardioreparation. Am J Cardiol 1992; 70: 27C–36C

    Article  PubMed  CAS  Google Scholar 

  2. Weber KT, Brilla CG, Cleland JGF, et al. Cardioreparation and the concept of modulating cardiovascular structure and function. Blood Press 1993; 2: 6–21

    Article  PubMed  CAS  Google Scholar 

  3. Purcell H, Coats A, Fox K, et al. Improving outcome after acute myocardial infarction: what is the role of ACE inhibitors? Br J Clin Pract 1995; 49: 195–9

    PubMed  CAS  Google Scholar 

  4. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161–72

    Article  PubMed  CAS  Google Scholar 

  5. Young JB. Angiotensin-converting enzyme inhibitors postmyocardial infarction. Cardiol Clin 1995; 13: 379–90

    PubMed  CAS  Google Scholar 

  6. Lonn EV, Yusuf S, Jha P, et al. Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056–69

    Article  PubMed  CAS  Google Scholar 

  7. Weber KT, Brilla CG, Campbell SE, et al. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 1993; 88 Suppl. 1: 107–24

    PubMed  CAS  Google Scholar 

  8. Sun Y, Ratajska A, Zhou G, et al. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993; 122: 395–403

    PubMed  CAS  Google Scholar 

  9. Kedra M, Kedrowa S, Rzesniowiecka G. Plasma renin activity in myocardial infarction. Cor Vasa 1972; 14: 16–21

    PubMed  CAS  Google Scholar 

  10. Neri-Serneri V, Parravicini I, Monza G, et al. Osservazioni sul comportamento dell’attivita reninica plasmatica nell’infarto miocardico acuto [in Italian]. G Ital Cardiol 1982; 12: 324–6

    Google Scholar 

  11. GISSI-3 Investigators. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 trial. Eur Heart J. In press

  12. Latini R, Nicolosi G, Maggioni AP, et al. The beneficial effect of lisinopril on left ventricular remodelling after a first myocardial infarction is modulated by age. The GISSI-3 Echo database [abstract no. 775-1]. J Am Coll Cardiol 1996; 27(2) Suppl. A: 281A

    Article  Google Scholar 

  13. Nicolosi GL, Latini R, Marino P, et al. The effects of early lisinopril treatment on left ventricular function after acute myocardial infarction: the echocardiographic results of the GISSI-3 study [abstract]. Eur Heart J 1995 Aug; 16 Suppl.: 96

    Google Scholar 

  14. Maggioni AP, For the GISSI-3 Investigators. Effects of lisinopril on left ventricular systolic function among different risk categories of patients evaluated by two-dimensional echocardiography 6 weeks after acute myocardial infarction: a GISSI-3 subanalysis on 14, 209 patients [abstract]. Eur Heart J 1994 Aug; 15 Suppl.: 102

    Google Scholar 

  15. Cleland JGF, Shah D, Krikler S, et al. Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. Br Heart J 1993; 69: 512–5

    Article  PubMed  CAS  Google Scholar 

  16. Arslan N, Özkan M, Erdol C, et al. The effect of lisinopril on left ventricular diastolic functions in patients with coronary artery disease [abstract]. Chest 1993 Mar; 103 Suppl.: 246S

    Google Scholar 

  17. Rabkin SW. Lisinopril increases the recovery during reoxygenation and resistance to oxidative damage in cardiomyocytes. Eur J Pharmacol 1993; 238: 81–8

    Article  PubMed  CAS  Google Scholar 

  18. Kabour A, Henegar JR, Devineni VR, et al. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res 1995; 29: 543–8

    PubMed  CAS  Google Scholar 

  19. Sun Y, Ratajska A, Weber KT. Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 1995; 126: 95–101

    PubMed  CAS  Google Scholar 

  20. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771–9

    Article  PubMed  CAS  Google Scholar 

  21. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107–15

    Article  PubMed  CAS  Google Scholar 

  22. Why HJF, Ansell H, Patel VB, et al. Antioxidant status in hypertension and effects of angiotensin converting enzyme inhibition. Biochem Soc Trans 1995; 23: 224S

    PubMed  CAS  Google Scholar 

  23. Nielsen FS, Rossing P, Ali S, et al. Effects of lisinopril and atenolol on left ventricular mass in hypertensive type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy [abstract]. Am J Hypertens 1994; 7: 40A

    Google Scholar 

  24. Tan SA, Tan LG, Berk LS. Regression of myocardial hypertrophy and improvement of ejection fraction after lisinopril therapy in hypertensive diabetics [abstract]. Circulation 1991 Oct; 84 Suppl. 2: 11–370

    Google Scholar 

  25. Handa S, Hamada M, Ura M, et al. Regression of increased left ventricular masses in elderly hypertensive patients on lisinopril as assessed by magnetic resonance imaging. Acad Radiol 1996; 3: 294–9

    Article  PubMed  CAS  Google Scholar 

  26. Wollert KC, Studer R, von Bülow B. Survival after myocardial infarction in the rat: role of tissue angiotensin-converting enzyme inhibition. Circulation 1994; 90: 2457–67

    Article  PubMed  CAS  Google Scholar 

  27. Riva E, Kurosaki M, Latini R. Effect of lisinopril and isosorbide-5-mononitrate on hemodynamics and mortality in rats with permanent coronary artery occlusion. J Cardiovasc Pharmacol 1992; 20: 490–5

    Article  PubMed  CAS  Google Scholar 

  28. Riva E, Kurosaki M, Porzio S, et al. Effects of an early treatment with lisinopril and isosorbide-5-mononitrate on hemodynamics and late ventricular remodelling in rats with 9-week myocardial infarction. Cardioscience 1995; 6: 139–46

    PubMed  CAS  Google Scholar 

  29. Maggioni AP, Pizzetti F, Santoro E, et al. Effects on ventricular arrhythmias of an early lisinopril treatment in patients with acute myocardial infarction: the GISSI-3 experience [abstract no. 902-36]. J Am Coll Cardiol 1996; 27(2) Suppl. A: 82A

    Article  Google Scholar 

  30. Chen X, Gillis CN, Bagchi D, et al. Lisinopril, ramiprilat and captopril reduce free radical-induced salicylate hydroxylation [abstract]. Circulation 1991 Oct; 84 Suppl. 2: 283

    Google Scholar 

  31. Gillis CN, Chen X, Merker MM. Lisinopril and ramiprilat protection of the vascular endothelium against free radicalinduced functional injury. J Pharmacol Exp Ther 1992; 262: 212–6

    PubMed  CAS  Google Scholar 

  32. Mira ML, Silva MM, Manso CF. The scavenging of oxygen free radicals by angiotensin converting enzyme inhibitors: the importance of the sulfhydryl group in the chemical structure of the compounds. Ann N Y Acad Sci 1994; 723: 439–41

    Article  PubMed  CAS  Google Scholar 

  33. Clapperton M, McMurray J, Beswick PH, et al. ACE inhibitors reduce free radical production, ex vivo, by human neutrophils [abstract]. Br J Clin Pharmacol 1991; 32: 661P

    Google Scholar 

  34. Kawahara J, Hsieh ST, Tanaka S, et al. Effects of lisinopril on lipid peroxidation, cell membrane fatty acids, and insulin sensitivity in essential hypertension with impaired glucose tolerance [abstract]. Am J Hypertens 1994; 7: 23A

    Google Scholar 

  35. Pasechnic M, Vataman E, Karaus A, et al. Long term lisinoporil therapy and platelet aggregation [abstract]. 54 (First International Meeting of the Working Group on Heart Failure; 1995 Apr 1–4; Amsterdam: European Society of Cardiology)

  36. Zannad F, Bray-Desboscs L, El Ghawi R, et al. Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. J Hypertens 1993; 11: 559–64

    Article  PubMed  CAS  Google Scholar 

  37. Graf K, Bossaller C, Baumgarten C, et al. Effect of ACE inhibitors on kinin metabolism in coronary artery [abstract]. Arch Int Pharmacodyn Ther 1990; 305: 249

    Google Scholar 

  38. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439–49

    Article  PubMed  CAS  Google Scholar 

  39. Virdis A, Mattei P, Ghiadoni L, et al. Effect of lisinopril on endothelial function in hypertensive patients [abstract]. Am J Hypertens 1995; 8: 178

    Article  Google Scholar 

  40. Hoffmann G, Pietsch R, Gobel BO, et al. Converting enzyme inhibition and vascular prostacyclin synthesis: effect of kinin receptor antagonism. Eur J Pharmacol 1990; 178: 79–83

    Article  PubMed  CAS  Google Scholar 

  41. Stark G, Stark U, Nagl S, et al. Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts. Clin Cardiol 1991; 14: 579–82

    Article  PubMed  CAS  Google Scholar 

  42. Yamada S, Kano M, Miwa Y, et al. Effect of lisinopril on cardiac arrhythmia of rats and on ECG of dogs [in Japanese]. Pharmacometrics 1993; 46: 89–98

    CAS  Google Scholar 

  43. Fahy G, Deb B, Robinson K, et al. The effects of lisinopril on serum catecholamine concentrations both at rest and on exercise in patients with congestive cardiac failure. A double blind, placebo controlled, parallel group study. Ir Med J 1993; 86: 134–5

    PubMed  CAS  Google Scholar 

  44. Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effect of quinapril or metoprolol on heart rate variability in postmyocardial infarction patients. Am J Cardiol 1996; 77: 242–6

    Article  PubMed  CAS  Google Scholar 

  45. Bonaduce D, Marciano F, Petretta M, et al. Effects of converting enzyme inhibition on heart period variability in patients with acute myocardial infarction. Circulation 1994; 90: 108–13

    Article  PubMed  CAS  Google Scholar 

  46. Perondi R, Saino A, Tio RA, et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 1992; 85: 2004–13

    Article  PubMed  CAS  Google Scholar 

  47. Kingma JH, van Gilst WH, Peels CH, et al. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994; 15: 898–907

    PubMed  CAS  Google Scholar 

  48. Zehetgruber M, Beckmann R, Gabriel H, et al. Effect of lisinopril on plasma levels of insulin and on parameters of endogenous fibrinolysis [abstract]. Thromb Haemost 1995; 73: 1009

    Google Scholar 

  49. Fogari R, Zoppi A, Malamani GD, et al. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 1995; 39: 471–6

    Article  PubMed  CAS  Google Scholar 

  50. Sushko E. Influence of lisinopril on blood coagulation and fibrinolysis in hypertensive patients of different age [abstract]. Eur Heart J 1994 Aug; 15 Suppl.: 195

    Google Scholar 

  51. Anning PB, Grocott-Mason RM, Lewis MJ, et al. Differential left ventricular relaxant effect of captopril and lisinopril [abstract]. Br Heart J 1995 May; 73 Suppl. 3: 59

    Google Scholar 

  52. Otterstad JE, Froeland G. Absorption, excretion and cardiovascular effects of oral lisinopril in patients with acute myocardial infarction. Clin Drug Invest. In press

  53. Lancaster SG, Todd PA. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646–69

    Article  PubMed  CAS  Google Scholar 

  54. Bendtsen F, Henriksen JH. Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. J Hum Hypertens 1989 Jun; 3 Suppl. 1: 139–45

    PubMed  Google Scholar 

  55. Case DE. The clinical pharmacology of lisinopril. J Hum Hypertens 1989 Jun; 3 Suppl. 1: 127–31

    PubMed  Google Scholar 

  56. Beermann B. Pharmacokinetics of lisinopril. Am J Med 1988; 85: 25–30

    Article  PubMed  CAS  Google Scholar 

  57. Beermann B, Till AE, Gomez HJ, et al. Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. Biopharm Drug Dispos 1989; 10: 397–409

    Article  PubMed  CAS  Google Scholar 

  58. Till AE, Dickstein K, Aarsland T, et al. The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. Br J Clin Pharmacol 1989; 27: 199–204

    Article  PubMed  CAS  Google Scholar 

  59. Thomson AH, Kelly JG, Whiting B. Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. Br J Clin Pharmacol 1989; 27: 57–65

    Article  PubMed  CAS  Google Scholar 

  60. Jackson B, Cubela RB, Conway EL, et al. Lisinopril pharmacokinetics in chronic renal failure. Br J Clin Pharmacol 1988; 25: 719–24

    Article  PubMed  CAS  Google Scholar 

  61. Neubeck M, Fliser D, Pritsch M, et al. Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure: consequence of dose adjustment. Eur J Clin Pharmacol 1994; 46: 537–43

    Article  PubMed  CAS  Google Scholar 

  62. Kelly JG, Doyle GD, Carmody M, et al. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. Br J Clin Pharmacol 1988; 26: 781–6

    Article  PubMed  CAS  Google Scholar 

  63. Flamenbaum W, Chadwick B, Degaetano C. Bioavailability of enalapril (E) and lisinopril (L) in subjects (S) with hepatic impairment (HI) [abstract]. Am J Hypertens 1991; 4: 33A

    Google Scholar 

  64. Johnston D, Duffin D. Pharmacokinetic profiles of single and repeat doses of lisinopril and enalapril in congestive heart failure. Am J Cardiol 1992; 70: 151C–3C

    Article  PubMed  CAS  Google Scholar 

  65. GISSI-3 Investigators. GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction. Am J Cardiol 1992; 70(10) Suppl.: 62C–9C

    Article  Google Scholar 

  66. GISSI-3 Investigators. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J Am Coll Cardiol 1996; 27: 337–44

    Google Scholar 

  67. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22

    Google Scholar 

  68. GISSI-3 Investigators. Effect of lisinopril treatment on early mortality in patients with acute myocardial infarction at different risk profile: data from the GISSI-3 study [abstract no. 902-35]. J Am Coll Cardiol 1996; 27(2) Suppl. A: 82A

    Google Scholar 

  69. GISSI-3 Investigators. Causes of early in-hospital mortality of patients with acute myocardial infarction: the impact of ACE-inhibitor treatment [abstract]. Circulation 1995; 92 Suppl. I: 1–673

    Google Scholar 

  70. Latini R, For the GISSI-3 Investigators. Renal effects of lisinopril after myocardial infarction. Results from GISSI-3 trial [abstract]. Eur Heart J 1994 Aug; 15 Suppl.: 429

    Google Scholar 

  71. Latini R, Avanzini F, De Nicolao A. Effects of lisinopril and nitroglycerin on blood pressure early after myocardial infarction: the GISSI-3 pilot study. Clin Pharmacol Ther 1994; 56: 680–92

    Article  PubMed  CAS  Google Scholar 

  72. Ball SG, Reynolds GW, Murray GD. ACE inhibitors after myocardial infarction [letter]. Lancet 1994; 343: 1632

    Article  PubMed  CAS  Google Scholar 

  73. Hall AS, Cooke GA, Tan LB. ACE inhibitors after myocardial infarction [letter]. Lancet 1994; 343: 1632–3

    Article  PubMed  CAS  Google Scholar 

  74. Kleist P. ACE inhibitors after myocardial infarction [letter; reply]. Lancet 1994; 343: 1633

    PubMed  CAS  Google Scholar 

  75. Morris JL, Cowan JC. ISIS-4 [letter]. Lancet 1995; 345: 1373

    Article  PubMed  CAS  Google Scholar 

  76. Julian DG. GISSI-3 [letter]. Lancet 1994; 344: 203

    Article  PubMed  CAS  Google Scholar 

  77. Tognoni G et al. ACE inhibitors after myocardial infarction [letter; reply]. Lancet 1994; 343: 1633–4

    Google Scholar 

  78. Tognoni G, Franzosi M, Latini R, et al. ISIS-4. GISSI-3 Investigators [letter]. Lancet 1995; 345: 1373–4

    PubMed  CAS  Google Scholar 

  79. Coats AJS. ACE inhibitors after myocardial infarction [letter]. Lancet 1994; 344: 475

    Article  PubMed  CAS  Google Scholar 

  80. Latini R, Maggioni AP, Zuanetti G, et al. Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? Cardiology 1996; 87 Suppl. 1: 16–22

    Article  PubMed  Google Scholar 

  81. Zuanetti G, GISSI-3 Investigators. Prognosis of diabetic patients post-MI: the role of ACE inhibitor treatment. J Diabetes Complications 1996; 10: 124–5

    Article  Google Scholar 

  82. Fallowfield JM, Blenkinsopp J, Raza A, et al. Post-marketing surveillance of lisinopril in general practice in the UK. Br J Clin Pract 1993; 47: 296–304

    PubMed  CAS  Google Scholar 

  83. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992; 117: 234–42

    PubMed  CAS  Google Scholar 

  84. De Lame P-A, Gabriel M, Malbecq W. Incidence of spontaneously reported cough in patients treated with lisinopril: a metanalysis of 21 studies [abstract]. Am J Hypertens 1992; 5: 123A

    Google Scholar 

  85. Rush JE, Lyle PA. Safety and tolerability of lisinopril in older hypertensive patients. Am J Med 1988 Sep 23; 85 Suppl. 3B: 55–9

    Article  PubMed  CAS  Google Scholar 

  86. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995; 92: 3132–7

    Article  PubMed  CAS  Google Scholar 

  87. GISSI-3 Investigators. Aspirin does not affect circulatory or renal effects of lisinopril early after myocardial infarction [abstract]. Circulation 1993; 88 (4 Pt 2) Suppl. 1: 1–556

    Google Scholar 

  88. Zeneca Pharmaceuticals. Lisinopril prescribing information. Wilmington, Delaware, USA, November 1995.

  89. Rush JE, Merrill DD. The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol 1987; 9 Suppl. 3: S99–107

    Article  PubMed  Google Scholar 

  90. Rees RS, Bergman J, Ramirez-Alexander R. Angioedema associated with lisinopril. Am J Emerg Med 1992; 10: 321–2

    Article  PubMed  CAS  Google Scholar 

  91. Santori P, Stacchiola T, Rossi M, et al. Immunohaemolytic anaemia associated with lisinopril treatment. Case report [in Italian]. Clin Ter 1993; 142: 517–20

    PubMed  CAS  Google Scholar 

  92. Harrison BD, Laidlaw ST, Reilly JT. Fatal aplastic anaemia associated with lisinopril [letter]. Lancet 1995; 346: 247–8

    Article  PubMed  CAS  Google Scholar 

  93. Schratzlseer G, Lipp T, Riess G, et al. Severe pancytopenia in an elderly woman after twelve months’ ACE inhibitor therapy [in German]. Dtsch Med Wochenschr 1994; 119: 1029–33

    Article  PubMed  CAS  Google Scholar 

  94. Maliekal J, Drake CF. Acute pancreatitis associated with the use of lisinopril. Ann Pharmacother 1993; 27: 1465–6

    PubMed  CAS  Google Scholar 

  95. Marinella MA, Billi JE. Lisinopril therapy associated with acute pancreatitis. West J Med 1995; 163: 77–8

    PubMed  CAS  Google Scholar 

  96. Dabaghi S. ACE inhibitors and pancreatitis [letter]. Ann Intern Med 1991; 115: 330–1

    PubMed  CAS  Google Scholar 

  97. Standridge JB. Fulminant pancreatitis associated with lisinopril therapy. South Med J 1994; 87: 179–81

    Article  PubMed  CAS  Google Scholar 

  98. Larrey D, Babany G, Bernuau J, et al. Fulminant hepatitis after lisinopril administration. Gastroenterology 1990; 99: 1832–3

    PubMed  CAS  Google Scholar 

  99. Droste HT, de Vries RA. Chronic hepatitis caused by lisinopril. Neth J Med 1995; 46: 95–8

    Article  PubMed  CAS  Google Scholar 

  100. Hilburn RB, Bookstaver D, Whitlock WL. Comment: angiotensin-converting enzyme inhibitor hepatotoxicity: further insights. Ann Pharmacother 1993; 27: 1142

    PubMed  CAS  Google Scholar 

  101. Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother 1993; 27: 228–31

    PubMed  CAS  Google Scholar 

  102. Sztern B, Salhadin A, Parent D, et al. Rash purpurique apres prise de lisinopril [in French]. Presse Med 1993; 22: 967

    PubMed  CAS  Google Scholar 

  103. Disdier P, Harlé J-R, Verrot D, et al. Adult Schonlein-Henoch purpura after lisinopril. Lancet 1992; 340: 985

    Article  PubMed  CAS  Google Scholar 

  104. Coulter DM, Pillans PI. Angiotensin-converting enzyme inhibitors and psoriasis. N Z Med J 1993; 106: 392–3

    PubMed  CAS  Google Scholar 

  105. Gilleaudeau P, Vallat VP, Carter DM, et al. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1993; 28: 490–2

    Article  PubMed  CAS  Google Scholar 

  106. Carvajal A, Lerida MT, Sanchez A, et al. ACE inhibitors and impotence: a case series from the Spanish Drug Monitoring System [letter]. Drug Saf 1995; 13: 130–1

    Article  PubMed  CAS  Google Scholar 

  107. Skop BP, Masterson BJ. Mania secondary to lisinopril therapy. Psychosomatics 1995; 36: 508–9

    Article  PubMed  CAS  Google Scholar 

  108. Savino LB, Haushalter NM. Lisinopril-induced ‘scalded mouth’ syndrome. Ann Pharmacother 1992; 26: 1381–2

    PubMed  CAS  Google Scholar 

  109. Subramanian D, Ayus JC. Case report: severe symptomatic hyponatremia associated with lisinopril therapy. Am J Med Sci 1992; 303: 177–9

    Article  PubMed  CAS  Google Scholar 

  110. Hume AL, Jack BW, Levinson P. Severe hyponatremia: an association with lisinopril? DICP 1990; 24: 1169–72

    PubMed  CAS  Google Scholar 

  111. Olayinka OF, Moody P, Palmer HM. The usefulness of a retrospective drug utilisation review carried out in a district general hospital in reducing cost of angiotensin-converting enzyme inhibitor prescribing. Br J Med Econ 1995; 8: 147–55

    Google Scholar 

  112. Anon. An ACE inhibitor after a myocardial infarction. Med Lett Drugs Ther 1994; 36: 69–70

    Google Scholar 

  113. McMurray J. ACE inhibitors after myocardial infarction [letter]. Lancet 1994; 344: 475–6

    Article  PubMed  CAS  Google Scholar 

  114. Walsh JT, Gray D, Keating NA, et al. ACE for whom? Implications for clinical practice of post-infarct trials. Br Heart J 1995; 73: 470–4

    Article  PubMed  CAS  Google Scholar 

  115. Cleland JGF. Gissi-3 [letter]. Lancet 1994; 344: 203–4

    Article  PubMed  CAS  Google Scholar 

  116. Jackson G. ACE inhibitors after myocardial infarction [editorial; comment]. Br J Clin Pract 1995; 49: 171

    PubMed  CAS  Google Scholar 

  117. Zeneca Pharma. Lisinopril prescribing information. In Dictionnaire Vidal, 72nd ed., Medirama Corp., Paris, pp. 1769–1771, 1996.

    Google Scholar 

  118. Mandal AK, Markert RJ, Saklayen MG. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure. Clin Nephrol 1994; 42: 170–4

    PubMed  CAS  Google Scholar 

  119. McLean AJ, Drummer OH, Smith HJ, et al. Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. J Hum Hypertens 1989 Jun; 3 Suppl. 1: 147–51

    PubMed  Google Scholar 

  120. Griffin JH, Hahn SM. Lisinopril-induced lithium toxicity [letter]. DICP 1991; 25: 101

    PubMed  CAS  Google Scholar 

  121. Fowler S. Lithium toxicity with ACE inhibitors. N Z Pharm 1995; 15: 33

    Google Scholar 

  122. Baldwin CM, Safferman AZ. A case of lisinopril-induced lithium toxicity. DICP 1990; 24: 946–7

    PubMed  CAS  Google Scholar 

  123. Teitelbaum M. A significant increase in lithium levels after concomitant ACE inhibitor administration. Psychosomatics 1993; 34: 450–3

    Article  PubMed  CAS  Google Scholar 

  124. Correa FJ, Eiser AR. Angiotensin-converting enzyme inhibitors and lithium toxicity. Am J Med 1992; 93: 108–9

    Article  PubMed  CAS  Google Scholar 

  125. Finley PR, O’Brien JG, Coleman RW Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J Clin Psychopharmacol 1996; 16: 68–71

    Article  PubMed  CAS  Google Scholar 

  126. The CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35

    Article  Google Scholar 

  127. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302

    Article  Google Scholar 

  128. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–8

    Article  PubMed  CAS  Google Scholar 

  129. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91

    Article  Google Scholar 

  130. De Bono DP, Hopkins A, for the Joint Audit Committee of the British Cardiac Society and the Royal College of Physicians. The management of acute myocardial infarction: guidelines and audit standards. J R Coll Physicians Lond 1994; 28: 312–7

    PubMed  Google Scholar 

  131. Fallen EL, Cairns J, Dafoe W, et al. Management of the postmyocardial infarction patient: a consensus report — revision of 1991 CCS guidelines. Can J Cardiol 1995; 11: 477–86

    PubMed  CAS  Google Scholar 

  132. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J 1996; 17: 43–63

    Google Scholar 

  133. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85

    Article  Google Scholar 

  134. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686–7

    Article  Google Scholar 

  135. Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80–5

    Article  PubMed  CAS  Google Scholar 

  136. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992; 327: 678–84

    Article  PubMed  CAS  Google Scholar 

  137. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8

    Google Scholar 

  138. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–77

    Article  PubMed  CAS  Google Scholar 

  139. Khber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–6

    Article  Google Scholar 

  140. Kuhn FE, Rackley CE. Coronary artery disease in women. Arch Intern Med 1993; 153: 2626–36

    Article  PubMed  CAS  Google Scholar 

  141. Benderly M, Behar S, Reicher-Reiss H, et al. Women after myocardial infarction fare worse than men. A 12-year follow-up of 1120 women and 3688 men surviving acute MI [abstract no. 771-4]. J Am Coll Cardiol 1996 Feb; 27 Suppl. A

  142. Maynard C, Litwin PE, Martin JS, et al. Gender differences in the treatment and outcome of acute myocardial infarction: results from the Myocardial Infarction, Triage and Intervention Registry. Arch Intern Med 1992; 152: 972–6

    Article  PubMed  CAS  Google Scholar 

  143. Tofler GH, Stone PH, Muller JE, et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol 1987; 9: 473–82

    Article  PubMed  CAS  Google Scholar 

  144. Anderson JL. Medical therapy for elderly patients who have had myocardial infarction: too little to the late in life? Ann Intern Med 1996; 124: 335–8

    PubMed  CAS  Google Scholar 

  145. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction. Evidence for undertreatment in women and the elderly. Arch Intern Med 1996; 156: 799–805

    Article  PubMed  CAS  Google Scholar 

  146. Pfeffer MA, Hennekens CH, Heart Study Executive Committee. When a question has an answer: rationale for our early termination of the HEART trial. Am J Cardiol 1995; 75: 1173–86

    Article  PubMed  CAS  Google Scholar 

  147. Borghi C, Ambrosioni E. A risk-benefit assessment of ACE inhibitor therapy post-myocardial infarction. Drug Saf 1996; 14: 277–87

    Article  PubMed  CAS  Google Scholar 

  148. Alexander W. ACE inhibitors after MI: searching for consensus. Patient Care 1994; 28: 15–6

    Google Scholar 

  149. Alderman CP, Rowett DS, Edwards S. The role of angiotensin converting enzyme inhibitors after myocardial infarction. Aust J Hosp Pharm 1995; 25: 511–4

    CAS  Google Scholar 

  150. Smith Jr SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. AHA Consensus Panel Statement. J Am Coll Cardiol 1995; 26: 292–4

    Article  PubMed  Google Scholar 

  151. ACE Inhibitor Myocardial Infarction (ACE-Inhibitor MI) Collaborative Group. Protocol for a collaborative systematic overview (meta-analysis) of individual patient data from the randomized controlled trials of the angiotensin converting enzyme inhibitors for the treatment of myocardial infarction. Zeneca Pharmaceuticals (UK), data on file, October 4, 1995.

  152. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–4

    Article  PubMed  CAS  Google Scholar 

  153. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990; 336: 542–5

    Article  PubMed  CAS  Google Scholar 

  154. Sramek JJ, Cutler NR, Seifert RD, et al. Compliance in hypertension: daily vs twice daily. Am J Hypertens 1993; 6: 1063

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Mairangi Bay, Private Bag 65901, Auckland 10, New Zealand

    Karen L. Goa & Julia A. Balfour

  2. Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy

    Giulio Zuanetti

Authors
  1. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia A. Balfour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giulio Zuanetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Various sections of the manuscript reviewed by: K. Arakawa, Department of Internal Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan; S.G. Ball, Institute for Cardiovascular Research, University of Leeds, Leeds, England; R. Latini, Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy; J.E. Otterstad, Division of Cardiology, Medical Department, Vestfold Central Hospital, Toensberg, Norway; M.A. Pfeffer, Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts, USA; B. Pitt, Department of Internal Medicine, Division of Cardiology, The University of Michigan Medical Center, Ann Arbor, Michigan, USA; H. Purcell, Department of Cardiology, Royal Brompton Hospital, London, England; K.T. Weber, School of Medicine, Department of Internal Medicine, University of Missouri, Columbia, Missouri, USA; K. Yamashita, The 2nd Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goa, K.L., Balfour, J.A. & Zuanetti, G. Lisinopril. Drugs 52, 564–588 (1996). https://doi.org/10.2165/00003495-199652040-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199652040-00011

Keywords

Search

Navigation